Pay in 4 interest-free payments of $6.81 Learn more
Ships within 48 hours · Estimated delivery Aug 21 - Aug 26
Outside the US it is supplied as a research-grade peptide and is not approved for human use by any major regulator
162,163 Retatrutide (LY-3437943), a novel triple agonist developed by Eli Lilly that targets GLP-1R, GIPR and GCGR, has shown potential in preliminary clinical data for providing excellent blood sugar control and significant weight reduction
GLP-1 Microdosing Chart & Schedule According to a 2,700-person real-world study presented at the 2025 European Congress on Obesity, participants achieved an average 16% weight loss over 64 weeks at microdose levels of semaglutide: Microdosing GLP-1 Weight Loss Results Microdose GLP-1 yields 5-10% body weight loss in year one versus 15-20% with full-dose treatment plans
15 Symptoms can be grouped into the following
For people who are put off by needles, or who simply prefer the routine of a daily tablet, it offers the established effects of semaglutide in a needle free form
US$ 21.29
US$ 29.02
US$ 28.83
US$ 25.34
